×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C
clinical
2,483 words
KG: ent-clin-3eeade26
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
Contents
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study t... (NCT05348785)
Knowledge Graph
Related Hypotheses (30)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
Stress Granule Phase Separation Modulators
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Orexin-Microglia Modulation Therapy
Score: 0.49
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.48
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.47
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Lysosomal Membrane Repair Enhancement
Score: 0.45
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Mitochondrial Transfer Pathway Enhancement
Score: 0.44
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
Lysosomal Positioning Dynamics Modulation
Score: 0.43
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.41
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.41
Mitochondrial RNA Granule Rescue Pathway
Score: 0.40
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.39
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.38
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.38
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35
Show 25 more
Related Analyses (6)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 1 more
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
See Also (15)
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
Section 253: Advanced Optogenetics and Chemogenetics fo
therapeutic · Pages share 4 hypotheses
Section 204: Advanced Proteostasis and Protein Quality
therapeutic · Pages share 4 hypotheses
Section 201: Advanced Mitochondrial Biogenesis and PGC-
therapeutic · Pages share 4 hypotheses
Section 194: Advanced Mitochondrial Dynamics and Biogen
therapeutic · Pages share 4 hypotheses
Mitochondrial Replacement Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Mitochondrial Biogenesis Inducers in Neurodegeneration
therapeutic · Pages share 4 hypotheses
Neurodegeneration
disease · Pages share 4 hypotheses
A 6-month & 18-month Prospective, Randomized, Placebo-c
clinical · Pages share 4 hypotheses
A Phase 2 Double-Blind, Randomized, Placebo-Controlled
clinical · Pages share 4 hypotheses
Synaptic Therapy Alzheimer's Research Trial (START): A
clinical · Pages share 4 hypotheses
A Multicenter, Phase III, Randomized, Double Blind, Pla
clinical · Pages share 4 hypotheses
A Phase III, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
A Phase IIB, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
Optogenetically-Modified Neurons in Neurodegeneration R
cell · Pages share 4 hypotheses
Show 10 more